Plaque Psoriasis

This interview segment involved a discussion with Gooderham regarding the implications of recent clinical trial findings for patients with scalp and body psoriasis.

In this interview, Gooderham highlights the ARRECTOR study findings which led to roflumilast foam’s supplemental new drug application to the FDA.

These data highlight gender differences related to dysmorphic concern and the prevalence of body dysmorphic disorder among those with various dermatologic disorders.

This supplemental new drug application for once-daily roflumilast foam follows positive results of the ARRECTOR phase 3 study.

These findings represent the first comprehensive research into the greater frequency of APS autoantibodies linked with treating psoriasis with TNF inhibitors.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

These data suggest that the introduction of the concept of circadian syndrome contributes to greater understanding of risk management for those with psoriasis.

These data highlight results on efficacy, quality of life, and tolerability of DMF within routine clinical practice among those with plaque psoriasis.

These data suggest that risk of developing psoriatic arthritis among patients with different variants of psoriasis vary based on race and sex as well.

A study with real-world data showed certolizumab pegol was effective in treating psoriasis a year later, with a probability of 1-year persistence at approximately 85%.

Awareness of these data may allow for dermatologists to better care for patients with anogenital pruritus as well as their families.

This analysis was done to verify the hypothesis that psoriatic arthritis is primarily genetically predetermined and distinct from the condition of psoriasis.

These findings highlight clinician versus patient perceptions of chronic pruritus assessment using patient-reported outcome measures.

Individuals with both psoriasis and hypertension have approximately a 2-fold increased mortality risk, which is greater than the mortality risk for psoriasis or hypertension alone.

These data highlight the association between risk of developing polyneuropathy and the presence of psoriasis and psoriatic arthritis.

In this analysis, the investigators looked at the impacts of the IL-23 inhibitor guselkumab on patients with psoriasis.

These data suggest the necessity of additional research to explore seborrheic dermatitis as well as its variations among many diverse groups and populations.

These data highlight several key points about COPD and its prevalence, risk, and incidence among plaque psoriasis patients.

In this clinical quiz, you will test your knowledge of psoriasis guidelines, with special focus on important clinical questions related to management of psoriasis and recent evidence-based recommendations.

This summary of major dermatology news covered in June highlights stories such as late-breaking data at RAD 2024, recent interviews, and recent FDA news.

The case series highlighted here was limited due to smaller numbers of participants, necessitating additional real-world data on bimekizumab for psoriasis.

These real-world findings on tildrakizumab’s use among patients with moderate-to-severe plaque psoriasis highlight the drug’s efficacy regarding high burden symptoms.

In this analysis, disparities associated with race, old age, socioeconomic differences, and rural residence were highlighted as examples.

These findings made comparisons between clinical outcomes of interclass and intraclass switching of biologic treatments among individuals with psoriasis.

These data were identified to expand upon existing information regarding treatment options for facial psoriasis and/or genital psoriasis.